Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I saw that, and I ask myself. If this company with a subpar TNBC drug can get $20b. Which would give us what $30+/share. We have several trials completed, and proven safety and efficiency. I again have to wonder if we have received similar deals, but Nader felt they were too low as he's stated several times this is a triple digit stock.
I'd gladly take a buyout for $30+/share
Tim drill results out 75 shares traded at $.06
Great interview with Dr. Drew, Dr. Yo, and covid survivors going on now.
Lower volume today. Hopefully we'll get an update on the uplisting by the end of next week
Perhaps the perfect storm is brewing? Cases are on the rise, we're coming into flu season, vaccines and therapeutics have crapped out. Remdisivir and Plasma don't do anything. Only a few left and not much time to do anything.
Up in Germany. $4.68US
https://www.bloomberg.com/quote/296:GR
Does anyone know if we've talked with Canada? If not any reasons why we wouldn't?
I agree there is a disconnect with management. I've stated it here previously. I think the company needs a new face, someone who is polished, clear and concise. That being said, the word still needs to get out about the drug and what it can do. The data speaks for itself, if Nader doesn't deliver something by September, I will not be voting for him to continue. I also agree we need to partner with a BP to get the ball over the line. I would hope Abbvie, as they already have a connection with us, and we have the next Humira. I don't know if any BP's made a reasonable offer and Nader shot it down because he thinks this is triple digits. I hope not, but we have no way of knowing. I can't imagine, Nader aside, that no BP is interested, they'd be buying the drug not Nader.
As an investor you should welcome anything that shines a positive light on our company/drug. It combats the crap out there like that WSJ article, in which it was written about something someone outside out company said?
Get on twitter and get the word out
https://twitter.com/search?q=%40katiecouric%20%23leronlimab&src=typed_query
Katie Couric is interviewing Dr. Fauci next week.
I've been here for years as well. I think we got screwed by the FDA on HIV. 81% efficiency with 350mg dose, soc was 42% range. They made us do 700mg before accepting. They should've granted approval with 350mg then asked for 700mg to see if it provided better efficiency.
The next 6 weeks are going to be exciting, there are many catalysts up in the air, with new developments happening more frequently. Word is spreading, not just here in our little group. #askfda on Twitter was 95% or people asking about leronlimab, there were a large amount of posters as well. In this day and age with social media being what it is. If leronlimab is as good as what the data states, there is no stopping it. Delays sure, but we'll get there.
Hey maybe it will get some traction. Somethings got to give, the approved treatments aren't working.
I guess that p value is made up then???
Why are you posting questions like this on the board. Email the company direct, then feel free to post the reply.
Put a list together and save them for the CC on Wednesday.
I don't think it is an application. I think it is a form stating everything is up to date, this is where we are, and what we have form for the record. If you scroll to the very bottom it was dated 8/31. So does the last trading day of the month have something to do with it? Is that part of uplisting/ NASDAQ requirements to continue?
You're trying way to hard to convince people this is a crap company, with a crap drug.
I'm showing 2.80€
Everyone has there part to play in a management role. Yes Nader is the face of Cytodyn, he can't do it all though. He's not fluent in statistical significance of trial data, he relies on Scott Kelly, or Dr J etc. Mike is the finance guy, he should know the ins and outs of the finances. Nader can not possibly know it all. I do agree with you that mistakes have been made, especially on the marketing side of things. Wall st reporter was a complete joke. We have 100m shares available, I would be ok with them exercising some to hire a top notch marketing team, hell even some lobbyist.
If that is the case, the BOD has a fiduciary responsibility to replace him. Not everything is his doing. Lets see what this week brings. I also want to add, as far as uplisting I would put that on Mike Muholland. You heard him speak on the CC's, the words came from his mouth not Nader.
I believe we have submitted M/M trial data to them and requested EUA.
For EUA request, not a 25 person trial, if I'm not mistaken?
At the end of the day, I'm convinced that we need a BP partner to get the ball across the line. I think Abbvie would be great, they currently have the highest grossing drug Humiria, and they are set to get royalties from us. Why not have another block buster drug??? They have a market cap of $1.66B. Twice that of Gilead.
It will be interesting for sure to hear why, if we are indeed denied. Per the company on several CC's we met the requirements. I expected some back and forth which will delay the 3rd week in August prediction. We either meet the requirements or we don't. If we don't then I will call that a failure on the company's part.
Mexico wanted a combo trial, that was answered in one of the CC's
If it were going to be denied, they would have said so in the comment letter, not asked for more information. It's a process just like the bla...
This is our Government. Thank you FDA...no proof they just have a feeling
The FDA said in its release that it has determined that it is “reasonable to believe” that remdesivir may be effective for the treatment of suspected or confirmed coronavirus cases in all hospitalized adults and children.
https://thehill.com/policy/healthcare/514243-fda-expands-use-of-remdesivir-as-covid-19-treatment
I would hope so...But I really doubt it, I think we're getting a phase 3
100% IF Leronlimab is what we all think it is based on all of the data. I can't imagine that not one BP company made an offer to partner with is. Did Nader push them away by trying to get an exorbitant dollar figure?
I'm going to go out on a limb and say yes, I assume so. Hence why we have an "update" call coming, I bet they announce the FDA wanted more data and moved us into a Phase 3! Junk
Remdesivir got expansion, so now they can treat ALL covid patients.
https://www.gilead.com/news-and-press/press-room/press-releases/2020/8/gileads-investigational-antiviral-veklury-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-p
Thanks bio, good stuff
They would most likely PR phase 3 was granted.
The WSJ wrote an article based on what someone outside the company said. Cytodyn NEVER mentioned being in talks with the OWS. Why the WSJ allowed such a hit piece to be published is SHAMEFUL.
Was the retraction from WSJ / proactive video what you were talking about, or is something bigger coming down the pipe?
UPDATE from Seeking alpha....POS
Update: In an interview posted on YouTube.com, CEO Nader Pourhassan took issue with the WSJ article saying the company never applied for inclusion in Operation Warp Speed and if it did, it wouldn't talk about. He questions the identity of the paper's Trump administration source who allegedly stated that it was not being considered for inclusion. He says investors should only buy CYDY stock if they believe in the company and its fundamentals. The SA article was based on the WSJ report.